Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents - Summary - MDSpire
Advertisement
Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents
To evaluate telomere length in tumor and adjacent non-tumorous liver tissues of HCC patients with chronic HCV, comparing DAA-treated and DAA-naive groups, as a potential prognostic biomarker for HCC development following DAA therapy, emphasizing its clinical significance.
Key Findings:
Telomere shortening is associated with chronic liver injury and inflammation, potentially increasing HCC risk.
DAA treatment may influence telomere dynamics and HCC risk, necessitating further exploration.
Telomerase reactivation is prevalent in HCC cases, enabling cancer cell immortalization.
Interpretation:
Telomere length may serve as a biomarker for assessing HCC risk in patients with chronic HCV, particularly in the context of DAA treatment.
Small sample size may affect generalizability of findings.
Conclusion:
The study highlights the potential of telomere length as a prognostic biomarker for HCC in patients treated with DAAs, warranting further investigation in larger cohorts.
